Risk factors, clinical course and long‐term prognosis in hidradenitis suppurativa: a cross‐sectional study

Kromann, Charles B; Deckers, Inge; Esmann, Solveig; Boer, Jurr; Prens, Errol P.; Jemec, Gregor B. E.

doi:10.1111/bjd.13090

Cited by 173 publications

(168 citation statements)

References 31 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…Therefore, lifestyle modification including smoking cessation, diet, and weigh loss have been proposed to enhance anti-HS drugs' efficacy, limiting HS severity, and favoring longer remission periods [76,81]. Particularly, smoking is not only a comorbidity but a well-established HS-aggravating factor.…”

Section: Treatmentmentioning

confidence: 99%

“…Smoking cessation is even more important when a patient is considering surgery because smoking undermines healing and significantly worsens surgical outcomes [82]. As regards obesity, it can show a deep negative effect on several outcomes since weight gain and related insulin resistance may favor the development of new HS lesions, especially in abdominal or submammary folds [75,81]. In addition, weight loss also leads to decreased friction in body folds, which is a proposed trigger factor for new HS lesion development [32].…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Scuderi

Monfrecola

Dessy

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease presenting with painful nodules, abscesses, sinus tracts, and scarring primarily affecting apocrine gland-rich intertriginous areas. HS prevalence ranges from 0.05 to 1%. The central pathogenic event in HS is believed to be the occlusion of the upper part of the folliculopilosebaceous unit, leading to the rupture of the sebofollicular canal with the consequent development of perifollicular lymphohistiocytic inflammation. The HS treatment choices are influenced by disease severity and its individual subjective impact, involving both medical and surgical interventions. However, given the chronic nature of HS, its destructive impact on social, working, and daily life of patients, its management is often frustrating for both the patient and physician. Hence, prompt and effective management strategies are urgently needed and a multidisciplinary approach is advocated. Therefore, in this article, we highlighted the main features of HS (clinical aspects, epidemiology, pathogenesis, diagnostic criteria, classifications, comorbidities, and treatments), so that awareness of this disease might be heightened in primary care physicians and surgeons, who may be the first health care providers to see patients with this disease owing to its characteristic clinical presentation (inflammatory nodules, abscesses, sinus tract, etc.).

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Scuderi

Monfrecola

Dessy

et al. 2017

Skin Appendage Disord

View full text Add to dashboard Cite

show abstract

“…18,48 An association between HS and current smoking was confirmed in a French cohort of 10 000 subjects but not in former smokers. 26 Conversely, smoking cessation may improve HS.…”

Section: -Smokingmentioning

confidence: 92%

Update on Hidradenitis Suppurativa (Part I): Epidemiology, Pathogenesis, Severity assessment and Comorbidities

Silva

Azevedo

Lisboa

2018

SPDV

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is as a chronic, inflammatory and recurrent skin disease of the hair follicle. Prevalence of HS is a matter of debate, with estimate rates as low as 0.00033% and as high as 4.1%. HS prevalence appears significantly higher in women and has a mean age of onset in the early 20s. The primary histopathologic event seems to be a follicular hyperkeratosis with plugging, dilatation and rupture of the hair follicle resulting with subsequent inflammation and formation of abscesses and sinus tracts. The cause of this is likely multifactorial, involving genetic factors, cigarette smoking, mechanical stress, obesity, immune aberrant response and hormonal abnormalities. HS, as a chronic inflammatory dermatosis, is associated with a variety of concomitant and secondary diseases such as metabolic syndrome, inflammatory and rheumatologic diseases, depression and malignancy, and, for this reason HS management often requires a multidisciplinary team.

show abstract

“…2 Data are limited regarding the effects of smoking cessation and weight loss on disease severity, however non-smokers are more likely to spontaneously remit. 5 There is evidence that HS is associated with other chronic inflammatory conditions, in particular inflammatory bowel disease. 6 The Hurley staging system is useful to define mild, moderate and severe disease (Fig 2 ).…”

Section: Epidemiology and Disease Severity Scalesmentioning

confidence: 99%

“…A possible endocrine cause is suggested by onset soon after puberty and a reported reduction in HS disease activity in around half of women after the menopause. 5 The microbiology of HS is complicated by sinus tracts and it is difficult to determine if bacteria are commensal or pathogenic. The pathophysiology of HS is also incompletely understood, but histologically, hyperkeratosis of the opening of hair follicles is an early event, which may cause accumulation of apocrine gland secretions, rupture of the hair follicle and a subsequent chronic foreign body reaction to the exposed hair shaft.…”

Section: Aetiologymentioning

confidence: 99%

Hidradenitis suppurativa: an update

Ingram

2016

Clinical Medicine

View full text Add to dashboard Cite

AHidradenitis suppurativa (HS) is a chronic, painful skin disease characterised by recurrent inflammatory lesions in flexural locations such as the axillae, groins and perineum. The papules, nodules and abscesses may discharge bloodstained pus which, combined with pain, results in marked quality-of-life reduction. Sinus tracts and scarring may also result. Onset of HS is typically in the second to fourth decades and it affects about 1% of young European adults. There are links with smoking and obesity and an autosomal dominant pattern of inheritance is reported by one-third of patients. Medical management escalates from topical antimicrobials to oral tetracyclines, a combination of clindamycin and rifampicin typically given for 10 weeks, oral disease modifiers, and anti-tumour necrosis factor-alpha therapies. Excision of individual lesions has high recurrence rates which can be minimised by wider excisions, at the expense of longer healing times. Treatment of pain is a relatively neglected aspect of therapy.

show abstract

Risk factors, clinical course and long‐term prognosis in hidradenitis suppurativa: a cross‐sectional study

Cited by 173 publications

References 31 publications

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Medical and Surgical Treatment of Hidradenitis Suppurativa: A Review

Update on Hidradenitis Suppurativa (Part I): Epidemiology, Pathogenesis, Severity assessment and Comorbidities

Hidradenitis suppurativa: an update

Contact Info

Product

Resources

About